Revenue segments as reported by the company.

Brands

Complex Gx and Biosimilars

Generics

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Litigation settlements and other contingencies, net

Acquired IPR&D

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Viatris

Viatris, Inc. is a global healthcare company, which engages in the provision of access to medicines and sustainable operations. It also offers support services such as diagnostic clinics, educational seminars, and digital tools. The firm operates through the following segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment consists of operations primarily in North America and Europe. The Greater China segment includes operations in mainland China, Taiwan and Hong Kong. The JANZ segment consists of operations in Japan, Australia and New Zealand. The Emerging Markets segment encompasses operations with developing markets and emerging economies including countries in Asia, the Middle East, South and Central America, Africa and Eastern Europe. The company was founded on February 14, 2019 and is headquartered in Canonsburg, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Viatris reports robust 2022 performance, eyes growth through strategic initiatives

Viatris showcased strong financial performance and strategic execution in 2022, with a focus on integration and debt reduction post-merger.
The company's emphasis on capital allocation, product launches, and market expansion highlights a balanced approach to growth and shareholder returns.
Challenges lie in effective debt management, successful product launches, and balancing R&D investments with capital returns for optimal growth.
Overall, Viatris remains poised for growth with opportunities in new product launches, market expansion, and revenue diversification in 2023.

Viatris reports robust Q1 earnings, eyes growth in key markets

Viatris delivered strong Q1 financial performance, reaffirmed 2023 guidance, and expressed confidence in strategic plan execution.
The company's focus on key therapeutic areas, successful acquisitions, and product developments position it for growth.
While facing challenges in base business erosion and market dynamics, Viatris is exploring opportunities in new products and strategic acquisitions for future growth.

Viatris reports robust Q2 earnings, eyes strategic divestitures for growth

Viatris (VTRS) had a strong Q2 2023, reaffirming guidance, showcasing revenue growth in key markets, and addressing analyst inquiries on tax structures and market impacts. The company's focus on strategic divestitures and therapeutic verticals presents growth opportunities amidst challenges in pricing and market dynamics.

Viatris reports robust Q3 results, navigates challenges for future growth

Viatris' Q3 performance reflects strong operational results, strategic divestitures, and a focus on shareholder value creation amidst challenges from FX and inflation.
The company's financial resilience, commitment to growth, and effective cost management underscore its ability to navigate market dynamics and drive long-term success.
With a solid foundation in place, Viatris remains well-positioned to capitalize on growth opportunities, drive innovation, and deliver value to shareholders.

Viatris reports strong 2023 performance and eyes transformational 2024

Viatris had a strong 2023 and anticipates a transformational 2024 with strategic investments and capital return to shareholders.
The company's collaboration with Idorsia for exclusive global rights to assets offers significant revenue growth potential and pipeline expansion.
Despite challenges like portfolio rationalization and FTC inquiry impact, Viatris is optimistic about future growth and product launches.

Viatris reports robust Q1 performance and charts growth opportunities

Viatris delivered strong financial performance, reaffirmed guidance, and introduced new revenue projections, showcasing stability and growth potential.
While facing divestiture challenges, the company's strategic initiatives, leadership additions, and pipeline progress position it for future success.
Opportunities for revenue growth, shareholder value enhancement, and innovation highlight Viatris' path towards sustained growth and market leadership.

Viatris excels in Q3 earnings, eyes growth through innovation

Viatris demonstrated strong financial performance in Q3 2024, showcasing revenue growth, debt repayment, and strategic investments. While facing challenges in Q4, the company remains committed to enhancing shareholder value and driving innovation. By leveraging its strengths and addressing key challenges, Viatris aims to seize growth opportunities and deliver long-term value to investors.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Did the biosimilars deal because they saw business slowing and wanted to create a low cost vertically-integrated player.

Viatris: Takeaways From Management At The Raymond James Conference

The stock crashed after the company reported earnings.

Is Viatris Stock in Trouble?

Viatris Inc. (VTRS) CEO Michael Goettler Presents at Raymond James 43rd Annual Institutional Investors Conference (Transcript)

Investors were unimpressed with the company's middling fourth-quarter earnings report.

Why Viatris Stock Dropped 24% in February

Its latest earnings report is full of red flags.

3 New Reasons to Sell Viatris Stock Right Now

EPAM Systems

Fidelity National Information

PayPal

Before plowing into some well-known names just because they've seen extreme price drops, take a step back and look at the bigger picture.

Is It Time to Buy the S&P 500's 5 Worst-Performing February Stocks?

After the stock's sharp downturn, there's a juicy opportunity waiting for daring investors.

Want to Be a Contrarian Investor? Buy Viatris Stock Now

This recently approved generic drug could benefit 5% to 15% of the overall population.

Viatris Just Snagged a Major FDA Approval

Viatris Inc. (NASDAQ: VTRS) shares have weakened more than 20% after the company reported fourth-quarter results this Monday. Fourth-quarter results and revenue outlook disappointed several banks and research companies, which lowered their price targets on Viatris shares.

Is Viatris a good buy opportunity after the current dip?

PITTSBURGH, March 1, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced the company will participate in the following investor conferences: Chief Executive Officer Michael Goettler and Chief Financial Officer Sanjeev Narula will participate in a fireside chat at the Raymond James 43rd Annual Institutional Investors Conference on Tuesday, March 8 th at 3:25 p.m. EST. President Rajiv Malik and Chief Financial Officer Sanjeev Narula will participate in a fireside chat at the Barclays Global Healthcare Conference on Wednesday, March 16 th at 10:45 a.m.

Viatris to Participate in Upcoming Investor Conferences

The less than satisfactory FQ4'21 revenues and Biocon deal left VTRS's stock prices in tatters with a 24% decline post-earnings call.

Viatris Stock: Why So Serious? Let's Put A Buy On Your Portfolio

Viatris, Inc. (VTRS) CEO Michael Goettler on Q4 2021 Results - Earnings Call Transcript

Viatris Inc (NASDAQ: VTRS) is trading lower Monday after the company reported worse-than-expected top-line results for the fourth quarter and issued guidance below estimates. Viatris reported quarterly revenue of $4.33 billion, which came in below the $4.35 billion.

Why Viatris Shares Are Trading Lower Today

Viatris Inc. said Monday it has agreed to combine its biosimilars portfolio with privately held Indian company Biocon Biologics Ltd. for up to $3.335 billion, as part of a broader overhaul of its business following a strategic review.

Viatris stock slides 24% as analysts say sale of biosimilars to Indian partner removes key growth driver

Viatris reported Q4-2021 results and gave mediocre guidance for 2022.

Viatris: Perhaps An Overreaction

Viatris Inc (NASDAQ: VTRS), previously known as Mylan, has agreed to pay $264 million to resolve a class-action lawsuit alleging it engaged in a scheme to delay generic competition to its EpiPen allergy treatment. The proposed settlement would resolve litigation following public.

Viatris To Pay $264M As EpiPen Antitrust Litigation Settlement: Reuters

Earnings that missed expectations and a soft outlook for 2022 disappointed investors.

Here's Why Viatris Stock Is Sliding on Monday

Viatris (VTRS) misses on Q4 earnings but surpasses sales estimates. The company announces a combination of its biosimilars portfolio with Biocon Biologics.

Viatris' (VTRS) Q4 Earnings Miss, Biocon Biologics Deal Inked

Viatris reported solid fiscal 2021 earnings, after having increased guidance on multiple occasions.

My Investment Thesis On Viatris Remains Intact After The Sale Of The Biosimilars Assets

Biocon Biologics Ltd has agreed to acquire Viatris Inc's (NASDAQ: VTRS) biosimilars assets for up to $3.335 billion in stock and cash. The deal value includes cash of up to $2.335 billion and Compulsorily Convertible Preference Shares in Biocon Biologics, valued at $1.

India-Based Biocon To Buy Viatris' Biosimilars Assets In $3.3B Deal

Viatris (VTRS) delivered earnings and revenue surprises of -2.44% and 0.71%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Viatris (VTRS) Q4 Earnings Miss Estimates

BENGALURU, India, Feb. 28, 2022 /PRNewswire/ -- Biocon Biologics Ltd., a subsidiary of Biocon Ltd.

Biocon Biologics to Acquire Viatris' Biosimilars Assets for up to USD 3.335 billion in Stock and Cash

(Reuters) -Viatris Inc, the drugmaker formerly known as Mylan, said on Monday it had agreed to pay $264 million to resolve a class action lawsuit alleging it engaged in a scheme to delay generic competition to its EpiPen allergy treatment.

Viatris to settle EpiPen antitrust litigation for $264 million

Viatris Inc. VTRS, +4.38% , the company formed by the merger of Mylan and Pfizer Inc. PFE, +3.83% unit Upjohn in 2020, said Monday it has reached an agreement to combine its biosimilars portfolio with Biocon Biologics Ltd. for up to $3.335 billion.

Viatris to contribute its biosimilars portfolio to Biocon Biologics for up to $3.335 billion, shares jump 4% premarket

PITTSBURGH, Feb. 28, 2022 /PRNewswire/ -- Biocon Biologics Transaction Consists of Pre-tax Consideration of up to $3.335 billion, Including $2 billion in Upfront Cash, $1 billion of Convertible Preferred Equity Representing a Stake of at Least 12.9% in Biocon Biologics (on a Fully Diluted Basis), and up to $335 million of Additional Payments. Rajiv Malik, Viatris President, to Represent Viatris on Biocon Biologics Board.

Viatris Reports Strong Fourth Quarter and Full-Year 2021 Financial Results; Issues 2022 Financial Guidance; Completes Comprehensive Strategic Review; Unveils Plan to Reshape the Company for the Future; Announces Combination of its Biosimilars Portfolio wi

News for Viatris Stock (VTRS)